Abstract
BackgroundMethotrexate (MTX) is the cornerstone of rheumatoid arthritis (RA) treatment, however, limitations of systemic exposure of oral MTX can affect its efficacy. The bioavailability of subcutaneous (SC) MTX is greater...
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have